CIP
ICPT

Chartwell Investment Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Chartwell Investment Partners’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-7,338
Closed -$740K – 469
2018
Q4 		$740K Buy
+7,338
New +$761K 0.03% 411
2016
Q4 		– Sell
-61,855
Closed -$10.2M – 445
2016
Q3 		$10.2M Buy
+61,855
New +$9.75M 0.18% 175

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Chartwell Investment Partners's ICPT Position: Q1 2019 in Review

Chartwell Investment Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2019, closing a stake of 7,338 shares — an estimated $740K sold.

Chartwell Investment Partners first reported a position in ICPT in Q3 2016 and held it in 2 quarters. The position peaked at $10.2M in Q3 2016. 202 funds tracked by Wall St. Rank hold ICPT as of Q1 2019.

  • Chartwell Investment Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Chartwell Investment Partners sold 7,338 Intercept Pharmaceuticals, Inc. shares in Q1 2019, an estimated $740K.
  • Chartwell Investment Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2016 and held it in 2 quarters.
  • Chartwell Investment Partners's Intercept Pharmaceuticals, Inc. position peaked at $10.2M in Q3 2016.
  • 202 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2019.

Based on Chartwell Investment Partners's 13F filing for Q1 2019, filed 11 Apr 2019.